How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease?

American Journal of Medicine

Volumn 102, Issue 1, 1997, Pages 54-59

  Sheline, Yvette I ^a,b,c   Freedland, Kenneth E ^a   Carney, Robert M ^a  

^a St Louis   (United States)

^b Department of Neurology ^*  (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450; DOXEPIN; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORTRIPTYLINE; OPIATE AGONIST; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

AGING; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; HEART ARRHYTHMIA; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEROTONIN SYNDROME;

AGE FACTORS; CORONARY DISEASE; DEPRESSION; DRUG INTERACTIONS; HEART; HUMANS; RISK; SEROTONIN UPTAKE INHIBITORS;

EID: 0031053807     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00374-9     Document Type: Article

References (75)

1. Schleifer SJ, Macari-Hinson MM, Coyle DA. The nature and course of depression following myocardial infarction. Arch Intern Med. 1989;149:1785-1789.
2. Carney RM, Freedland KE, Jaffe AS. Insomnia and depression prior to myocardial infarction. Psychosom Med. 1990;52(6):603-609.
3. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6 month survival. JAMA. 1993;270:1819-1825.
4. Forrester AW, Lipsey JR, Teitelbaum ML, et al. Depression following myocardial infarction, Int J Psychiat Med. 1992;22:33-46.
5. Carney RM, Rich MW, teVelde A, et al. Major depressive disorder in coronary artery disease. Am J Cardiol. 1987;60(16):1273-1275.
6. Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med. 1988;50:627-633.
7. Ahern DK, Gorkin L, Anderson JL, et al. Biobehavioral variables and mortality or cardiac arrest in the cardiac arrhythmia pilot study (CAPS). Am J Cardiol. 1990;66(1):59-62.
8. Falger P, Appels A. Psychological risk factors over the life course of myocardial infarction patients. Adv Cardiol. 1982;29:132-139.
9. Garrity TF, Klein RF. Emotional response and clinical severity as early determinants of six-month mortality after myocardial infarction. Heart Lung. 1975;4:730-737.
10. Schleifer SJ, Macari MM, Slater W, et al. Predictors of outcome after myocardial infarction: role of depression. Circulation. 1974;2:2-10.
11. Stern JJ, Pascale L, Ackerman A. Life adjustment post myocardial infarction: determining predictive variables. Arch Intern Med. 1977;137:1680-1685.
12. Silverstone PH. Depression and outcome in acute myocardial infarction. BMJ. 1987;294:219-220.
13. Ladwig KH, Kieser M, Konig J, et al. Affective disorders and survival after acute myocardial infarction. Eur Heart J. 1991;12:959-964.
14. Anda R, Williamson D, Jones D, et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology. 1993;4:285-294.
15. Kennedy GJ, Hofer MA, Cohen D, et al. Significance of depression and cognitive impairment in patients undergoing programmed stimulation of cardiac arrythmias. Psychom Med. 1987;49:410-421.
16. Kurosawa H, Shimizu Y, Hirose S, Takano T. The relationship between mental disorders and physical severities in patients with acute myocardial infarction. Jpn Circ J. 1983;47:723-728.
17. Wynn A. Unwarranted emotional distress in men with ischaemic heart disease. Med J Australia. 1967;6:847-851.
18. Mayou R, Foster A, Williamson B. Medical care after myocardial infarction. J Psychosom Res. 1979;23:23-26.
19. Stern TA, Caplan RA, Cassem NH. Use of benzodiazepines in a coronary care unit. Psychosomatics. 1987;28(1):19-23.
20. Freedland KE, Lustman PF, Carney RM, Hong BA. Underdiagnosis of depression in patients with coronary artery disease: the role of nonspecific symptoms. Int J Psych Med. 1992;22:221-229.
21. Pary RP, Tobias CR, Lippmann S. Antidepressants and the cardiac patient: selecting an appropriate medication. Postgrad Med. 1989;85(1):267-269.
22. Warrington SJ, Padgham C, Lader M. The cardiovascular effects of antidepressants. Psychol Med. 1989;Supplement 16:1-40.
23. Glassman AAH, Bigger JT Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review. Arch Gen Psych. 1981;38:815-820.
24. Glassman AH, Roose SP, Giardina EGV. Cardiovascular effects of tricyclic antidepressants. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987:1437-1442.
25. Giardana EGV, Bigger JT, Jr., Johnson, LL. The effect of imipramine and nortriptyline on ventricular premature depolarizations and left ventricular function. Circulation. 1981;64(4):316.
26. Glassman AH. The newer antidepressant drugs and their cardiovascular effects. Psychopharm Bull. 1984;20:272-279.
27. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. NEJM. 1987;316:363-369.
28. Glassman AH, Bigger JT Jr, Giardina EGV, et al. Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet. 1979;1:468-472.
29. Muller OF, Goodman N, Bellet S. The hypotensive effect of imipramine hydrochloride in patients with cardiovascular disease. Clin Pharmacol Therapeut 1961;2:300-307.
30. Thayssen P, Bjerre M, Kragh-Sprensen P, et al. Cardiovascular effects of imipramine and nortriptyline in elderly. Psychopharmacol. 1981;74:360-364.
31. Bigger JT Jr, Giardina EGV, Perel JM, et al. Cardiac antiarrhythmic effect of imipramine hydrochloride. NEJM. 1977;296:206-208.
32. Giardina EGV, Bigger JT, Glassman AH, et al. Effects of desmethylimipramine and imipramine on left ventricular function and the ECG: a randomised crossover design. Int J Cardiol. 1983;2:375-385.
33. Dietch JT, Fine M. The effect of nortriptyline in elderly patients with cardiac conduction disease. J Clin Psych. 1990;51:65-67.
34. Stern TA. The management of depression and anxiety following myocardial infarction. Mt Sinai J Med. 1985;52(8):623-633.
35. Fisch C, Knoebel SB. Electrocardiographic findings in sertraline depression trials. Drugs. 1992;4:305-312.
36. Upward JF, Edwards JG, Goldie A, et al. Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol. 1988;26:399-402.
37. Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psych. 1991;52:174-176.
38. Ahmed I, Dagincourt PG, Miller LG, et al. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry. 1993;38:62-63.
39. Roberge RJ, Martin TG. Mixed fluoxetine/loxapine overdose and atrial flutter. Ann Emerg Med. 1994;23:586-590.
40. Amital D, Amital H, Gross R, et al. Sinus bradycardia due to fluvoxamine overdose. Br J Psych. 1994;165:553-554. Letter.
41. Langlois RP, Paquette D. Sustained bradycardia during fluvoxamine and buspirone intoxication. Can J Psych. 1994;39:126-127. Letter.
42. Henry JA. Overdose and safety with fluvoxamine. Int Clin Psychopharmacol. 1991;6:41-47.
43. Drake WM, Gordon GD. Heart block in a patient on propranolol and fluoxetine. Lancet. 1994;343:425-426. Letter.
44. Gardner SF, Rutherford WF, Munger MA, Panacek EA. Drug-induced supraventricular tachycardia: a case report of fluoxetine. Ann Emerg Med. 1991;20:194-197.
45. Borys DJ, Seltzer SC, Ling LL, et al. Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med. 1992;10:115-120.
46. Chiang WK, Ford M, Wax P, et al. Prospective evaluation of fluoxetine ingestions. Vet Hum Toxicol. 1990;32:348. Abstract.
47. Borys DJ, Seltzer SC, Ling LF, et al. Acute fluoxetine overdose. Vet Hum Toxicol. 1990;32:348. Abstract.
48. Jenkins J, Shannon MW, Woolf A. Fluoxetine inotxication. Vet Hum Toxicol. 1990;32:348. Abstract.
49. Kincaid RL, McMulin MM, Crockham SB, et al. Report of a fluoxetine fatality. J Anal Toxicol. 1990;14:327-329.
50. Spier SA, Frontera MA. Unexpected deaths in depressed medical inpatients treated with fluoxetine. J Clin Psych. 1991;52:377-382.
51. Amstein R, Fetkovska N, Ferracin F, et al. Serotonin metabolism and age-related effects of antihypertensive therapy with ketanserin. Drugs. 1988;36:61-66.
52. Golino P, Piscione F, Willerson JT, et al. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. NEJM. 1991;324:641-648.
53. McFadden EP, Clarke JG, Davies GJ, et al. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. NEJM. 1991;324:648-654.
54. Hillis LD, Lange RA. Serotonin and acute ischemic heart disease. NEJM. 1991;324:688-689.
55. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig. 1993;71:1002-1009.
56. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34:262-265.
57. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psych. 1996;153:311-320.
58. Lane R, Baldwin D, Preskorn S. The SSRIs: advantages, disadvantages and differences. J Psychopharmacol. 1995;92:163-178.
59. Hale AS. New antidepressants: use in high-risk patients. J Clin Psych. 1993;54:61-70.
60. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;149:705-713.
61. Neuvonen P, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 1993;342:1419.
62. Suchowersky O, de Vries J. Interaction of fluoxetine and selegiline. Can J Psychiatry. 1990;35:571-572. Letter.
63. Grimsley S, Jann M, Carter G, D'Soouza M. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther. 1991;50:10-15.
64. Coplan J, Gorman J. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry. 1993;150:837.
65. Gerson SC, Plotkin DA, Jarvik LF. Antidepressant drug studies, 1964 to 1986: empirical evidence for aging patients. J Clin Psychopharmacol. 1988;8:311-322.
66. Nyeth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a nordic multicentre study. Brit J Psychiatry. 1990;157:894-901.
67. Tollefson GD, Holman SL. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol. 1993;8:253-259.
68. Feighner JP, Conn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry. 1985;46:20-25.
69. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry. 1991;48:851-855.
70. Feighner JP, Boyer WF, Meredith CH, Hendrickson G. An overview of fluoxetine in geriatric depression. Br J Psychiatry. 1988;153:105-108.
71. Dunner DL, Cohn JB, Walshe T, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry. 1992;53(suppl 2):57-60.
72. Hutchinson DR, Tong S, Moon CAL, et al. Paroxetine in the treatment of elderly depressed patients in general parctice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol. 1992;6(suppl 4):43-51.
73. Schone W, Ludwig M: A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol. 1993;13(suppl 2):34S-39S.
74. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psych. 1994;151:1735-1739.
75. Laghrissi-Thode F, Kennedy J, Nelson JC, et al. Nortriptyline versus paroxetine in depressed ischemic heart disease patients: a multicenter randomized double-blind clinical trial. Abstract presented at the American College of Neuropsychopharmacology (ACNP), San Juan, Puerto Rico, December 1995.